Page 109 - JCTR-11-5

Journal of Clinical and
Translational Research Uric acid, CTGF genotype, and prostate cancer

our surveillance system was highly comprehensive, (#18-02). Written informed consent was obtained from
supported by the fact that our study was conducted in an participants or, when they were unable, from their families
island population, which allowed for meticulous follow-up. or caregivers, for clinical examinations, procedures, and
access to medical records for disease surveillance.
5. Conclusion
In this population-based cohort study, we found that the Consent for publication
effect of serum uric acid on prostate cancer incidence, All participants provided written consent for publication of
whether protective or harmful, varies according to an their de-identified data at each Kuakini-HHP examination.
individual’s CTGF rs9399005 genotype. Men who were
homozygous for the CTGF common allele (C) and had Availability of data
hyperuricemia exhibited the highest risk of prostate cancer Data used in this work are available from the corresponding
compared to other exposure groups. These findings suggest author or Dr. Kamal H. Masaki (km1@hawaii.rr.com)

that lowering uric acid levels in this subgroup may help upon reasonable request.
reduce prostate cancer risk. Further research is needed to
confirm these results. References
Acknowledgments 1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality
We thank all study participants and their families for worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
their cooperation over many decades, the Hawaii State 2024;74(3):229-263.
Department of Health for their help, Ayako Elliott and doi: 10.3322/caac.21834
Eva Ardo for their assistance with genotyping, and Hiromi 2. Leslie SW, Soon-Sutton TL, Skelton WP. Prostate Cancer.
Nakada and Ka-On Fong for monitoring the vital status of StatPearls. Available from: https://www.ncbi.nlm.nih.gov/
Kuakini-HHP participants. books/nbk470550 [Last accessed on 2024 Oct 4].

Funding 3. Clebak KT, Morrison A, Croad JR. Gout: Rapid evidence
review. Am Fam Physician. 2020;102(9):533-538.
This work was supported by NIH (Contract
N01-AG-4-2149, Grants 5U01AG019349-05, 4. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G.
Purine-rich foods, dairy and protein intake, and the risk of
5R01AG027060 [Kuakini Hawaii Lifespan Study], gout in men. N Engl J Med. 2004;350(11):1093-1103.
5R01AG038707 [Kuakini Hawaii Healthspan Study],
and 1P20GM125526-01A1 [Kuakini HHP Center doi: 10.1056/NEJMoa035700
of Biomedical Research Excellence for Clinical and 5. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G.
Translational Research on Aging]); the National Heart, Alcohol intake and risk of incident gout in men: A prospective
Lung, and Blood Institute (Contract N01-HC-05102); and study. Lancet. 2004;363(9417):1277-1281.
the National Cancer Institute (Contracts N01-CP-33216, doi: 10.1016/S0140-6736(04)16000-5
N01-CN-55424, N01-CA-15655, and N01-CP61060
[Kuakini Japan-Hawaii Cancer Study]). 6. Sangkop F, Singh G, Rodrigues E, Gold E, Bahn A. Uric acid:
A modulator of prostate cells and activin sensitivity. Mol Cell
Conflict of interest Biochem. 2016;414:187-199.
doi: 10.1007/s11010-016-2671-8
The authors declare that they have no competing interests.
7. Kim YR, Choi CK, Lee YH, et al. Association between
Author contributions albumin, total bilirubin, and uric acid serum levels and the
risk of cancer: A prospective study in a Korean population.
Conceptualization: Randi Chen Yonsei Med J. 2021;62:792-798.
Investigation: Randi Chen, Timothy A. Donlon
Methodology: Randi Chen, Kamal H. Masaki doi: 10.3349/ymj.2021.62.9.792
Writing–original draft: Randi Chen 8. Chen CJ, Yen JH, Chang SJ. Gout patients have an increased
Writing–review & editing: All authors risk of developing most cancers, especially urological
cancers. Scand J Rheumatol. 2014;43:385-390.
Ethics approval and consent to participate doi: 10.3109/03009742.2013.878387
This prospective study was conducted in the Department 9. Benli E, Cirakoglu A, Ayyıldız SN, Yüce A. Comparison of
of Research, Kuakini Medical Center, and was approved by serum uric acid levels between prostate cancer patients and
the Institutional Review Board of Kuakini Medical Center a control group. Cent European J Urol. 2018;71:242-247.

Volume 11 Issue 5 (2025) 103 doi: 10.36922/JCTR025260029